Item 8.01 Other Events.
On January 21, 2020, Genprex, Inc. (the "Company") issued a press release
announcing that the U.S. Food and Drug Administration had granted Fast Track
Designation for the Company's Oncoprex™ immunogene therapy in combination with
epidermal growth factor receptor (EGFR) inhibitor osimertinib (AstraZeneca's
Tagrisso®) for the treatment of non-small cell lung cancer patients with EFGR
mutations that progressed after treatment with osimertinib alone. The full text
of the press release is attached to this Current Report on Form 8-K as Exhibit
99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Press Release dated January 21, 2020, issued by Genprex, Inc.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses